Name: Anti-Human CD38 (Daratumumab Biosimilar)
Brand: InnoCyto
SKU: 501803
Price: 1390 USD
Availability: InStock

Shop Now Contact

Anti-Human CD38 (Daratumumab Biosimilar)

InnoCyto Product Image

Cat #	Size	Price
501801	1 mg	$175
501802	5 mg	$590
501803	20 mg	$1390

Bulk/Custom

Product Details

Clone	Daratumumab
Application	Flow cytometry, animal model study
Host Species	Mammalian cells
Reactivity	Human
Format	Liquid
Product Description	Anti-Human CD38 (Daratumumab Biosimilar)
Isotype	Human IgG1
Regulatory Status	RUO
Clonality	Recombinant
Immunogen	Human CD38
Species specificity	Human
Purity	>95% by reducing SDS-PAGE
Grade	In vivo
Storage Conditions	4ºC
Maximal Shelf Life	12 months
Target Name	CD38, gp45, Cyclic ADP-ribose hydrolase 1,T10, ADP-ribosyl cyclase
Antibody Type	Recombinant
Research Areas	Cancer Marker, T cells, B cells, NK cells, Monocytes, Macrophages, Plasma cells
See All Formats	Clone Daratumumab

Background Information

Daratumumab is a fully human monoclonal antibody belonging to the immunoglobulin G1 kappa (IgG1κ) subclass. It was developed using recombinant DNA technology and produced in mammalian expression systems such as Chinese Hamster Ovary (CHO) cells to maintain human-like post-translational modifications including glycosylation and disulfide linkage formation. The molecule has a molecular weight of approximately 148 kilodaltons (kDa) and consists of two identical heavy chains and two identical light chains connected by disulfide bonds, forming the canonical Y-shaped IgG antibody structure. Each heavy chain contains one variable (VH) and three constant (CH1–CH3) domains, while each light chain contains one variable (VL) and one constant (CL) domain.

The antigen-binding sites of Daratumumab are located within the complementarity-determining regions (CDRs) of the VH and VL domains, which confer specificity toward CD38, a transmembrane glycoprotein expressed at varying densities on many cell types. The binding interface between Daratumumab and CD38 is characterized by high-affinity interactions involving hydrogen bonding, hydrophobic forces, and electrostatic complementarity. Structural studies have shown that Daratumumab binds to a conformational epitope on CD38 composed of both protein and carbohydrate residues, highlighting its precise steric complementarity with the target antigen. This interaction enables the antibody to influence CD38’s enzymatic and receptor-mediated functions in experimental models, such as those modulating calcium signaling and cellular adhesion.

The Fc (fragment crystallizable) region of Daratumumab, typical of IgG1 molecules, promotes molecular stability and mediates effector interactions by engaging Fc gamma receptors (FcγRs) on immune cells and the complement protein C1q. These engagements can initiate immune mechanisms such as complement-dependent cytotoxicity (CDC) and antibody-dependent cellular cytotoxicity (ADCC) under laboratory conditions. Additionally, the Fc region interacts with neonatal Fc receptors (FcRn), extending the antibody’s circulatory half-life through recycling.

Frequently Asked Questions

What are InnoCyto Biosimilar products?

InnoCyto biosimilars are research-grade recombinant antibodies or proteins engineered to closely replicate the sequence, structure, and target-binding activity of approved or well-characterized therapeutic antibodies (e.g., checkpoint inhibitors, anti-cytokine biologics). They are intended for research use to study the mechanism of action, efficacy, and combination potential of these therapeutic classes without the cost or access restrictions of clinical-grade material.

How similar are these biosimilars to the original therapeutic antibody?

Each biosimilar is produced using the published or inferred variable region sequence of the reference therapeutic and is expressed recombinantly to match the parent antibody's target specificity, isotype, and general binding profile. While designed for high functional similarity, InnoCyto biosimilars are for research use only and are not clinically validated equivalents of the approved drug product.

Are these antibodies suitable for in vivo studies?

Yes. InnoCyto biosimilars are manufactured with the same low-endotoxin, azide-free, carrier-free standards used across our in vivo product lines, making them suitable for animal efficacy, combination, and mechanism-of-action studies. Product pages indicate whether a given biosimilar is validated for in vivo use, in vitro use, or both.

What is the difference between a biosimilar and a recombinant "research antibody" targeting the same protein?

A biosimilar is specifically designed to mimic a known, named therapeutic antibody (matching its clinical target epitope and mechanism), whereas a general recombinant research antibody may target the same protein but bind a different epitope or lack the same functional properties. Biosimilars are the right choice when your study is benchmarking against, or modeling the action of, an approved or clinically studied biologic.

What quality and purity standards do biosimilar antibodies meet?

All biosimilars undergo the same rigorous QC pipeline as our other antibody lines: ≥95% purity by SDS-PAGE/SEC-HPLC, low-endotoxin testing via LAL assay, and binding/functional validation against the intended target. Certificates of Analysis (CoA) are provided per lot with full specifications.

Which therapeutic targets and mechanisms are covered in the Biosimilar line?

The line spans major immuno-oncology and immunology targets, including immune checkpoint pathways (e.g., PD-1/PD-L1, CTLA-4), cytokine and cytokine-receptor blockers, and other clinically relevant mechanisms. See each product page for the specific reference therapeutic and mechanism of action represented.

Have a product or application question? Consult our FAQs or contact us.

Search Tips